文献速递血栓与止血

在综合癌症中心对新型癌症相关血栓形成电子风险评分的外部验证

External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center.
PubMed 文献 · Am J Hematol · 2023-04-17

在MD安德森癌症中心2017年1月至2021年1月确诊的21142例成人癌症患者中,外部验证新型电子健康记录静脉血栓栓塞风险评分。6个月内静脉血栓栓塞发生率为5.7%,新评分c统计量为0.71(95%CI 0.69-0.72),优于Khorana评分的0.64(95%CI 0.62-0.65),且校准良好。

要点

  • 新评分6个月VTE发生率随评分升高而增加,0分1.3%至5+分13.8%。
  • 新评分c统计量0.71(95%CI 0.69-0.72),Khorana评分0.64(95%CI 0.62-0.65)。
  • 新评分将20%的Khorana评分重新分类,高风险组捕获的VTE增加25%。

核心结论

  • 新评分在不同人口学特征队列中表现出一致的区分度和校准度,可能成为选择高风险人群进行临床试验和VTE监测的新标准。

研究设计与样本

  • 在MD安德森癌症中心肿瘤登记处识别2017年1月至2021年1月确诊的成人癌症患者,进行独立外部验证。
  • 共纳入21142例癌症患者,中位随访8.1个月,VTE通过机构特定的自然语言处理放射学算法确认(阳性预测值94.8%)。

主要发现

  • 6个月内共发生1067例(5.7%)VTE。
  • 新评分0、1、2、3、4、5+分的分布分别为5661、3558、3462、3489、2918、2054例,对应6个月VTE发生率分别为1.3%、3.1%、5.4%、7.3%、9.3%、13.8%。
  • 新评分c统计量为0.71(95%CI 0.69-0.72),校准良好;Khorana评分c统计量为0.64(95%CI 0.62-0.65)。
  • 两种风险评分一致性为80%;新评分重新分类20%的Khorana评分(低危转高危3530例,VTE发生率9.0%;高危转低危734例,VTE发生率3.4%),高风险组捕获的VTE增加25%。

临床怎么用

  • 作者认为新评分可能成为选择高风险人群进行临床试验和VTE监测的新标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is a significant complication for cancer patients undergoing systemic therapy. We performed an independent external validation for a recently derived and validated a novel electronic health record (EHR) VTE risk score in a comprehensive cancer center. Adult patients with incident cancer diagnoses were identified from MD Anderson Cancer Center Tumor Registry 1/2017-1/2021. Baseline covariates extracted at the time of first-line systemic therapy included demographics, cancer site/histology, stage, treatment, complete blood count, body mass index, recent prolonged hospitalization, and history of VTE or paralysis. VTE was ascertained using an institution-specific natural language processing radiology algorithm (positive predictive value of 94.8%). The median follow-up for 21 142 cancer patients was 8.1 months. There were 1067 (5.7%) VTE within 6 months after systemic therapy. The distribution of the novel score for 0-, 1, 2, 3, 4, 5+ was 5661, 3558, 3462, 3489, 2918, and 2054; while the corresponding 6-month VTE incidence was 1.3%, 3.1%, 5.4%, 7.3%, 9.3%, and 13.8%, respectively (c statistic 0.71 [95% CI 0.69-0.72] with excellent calibration). In comparison, the Khorana score had a c statistic of 0.64 [95% CI 0.62-0.65]. The two risk scores had 80% concordance; the novel score reclassified 20% of Khorana score (3530 low-to-high with 9.0% VTE; 734 high-to-low with 3.4% VTE) and led to a 25% increment in VTEs captured in the high-risk group. In conclusion, the novel score demonstrated consistent discrimination and calibration across cohorts with heterogenous demographics. It could become a new standard to select high-risk populations for clinical trials and VTE monitoring.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Li A, De Las Pozas G, Andersen CR, et al. External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center. Am J Hematol. 2023. PMID: 37067102. doi:10.1002/ajh.26928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。